Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zopapogene imadenovec in recurrent respiratory papillomatosis
NCT06538480Phase 4Recruiting
- Sponsor
- Precigen
- Start
- Jul 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 4, open-label trial of zopapogene imadenovec in recurrent respiratory papillomatosis (RRP) (2 cohorts), sponsored by Precigen. Primary endpoints: Adenoviral Vector Shedding at 6 weeks and Complete Response Rate at 12 months. Started Jul 2024; status: recruiting.
02
Drugs
zopapogene imadenovec
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT06538480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538480.